Login to Your Account

Three Strikes for Glybera; AMT Is Likely Out, of Business

By Nuala Moran
Staff Writer

Monday, April 23, 2012

LONDON – The European Medicines Agency (EMA) has given a thumbs down to the gene therapy Glybera (alipogene tiparvovec) for the third time after being asked by the European Commission to think again about its refusal in January to recommend approval of the treatment for the inherited disorder lipoprotein lipase deficiency (LPL).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription